Press release
Respiratory Syncytial Virus Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
Discover the latest drugs and treatment options in the Respiratory Syncytial Virus Pipeline. Dive into DelveInsight's comprehensive report today! @ Respiratory Syncytial Virus Pipeline Outlook [https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from Respiratory Syncytial Virus Pipeline Report
* DelveInsight's Respiratory Syncytial Virus pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for Respiratory Syncytial Virus treatment.
* The leading Respiratory Syncytial Virus Companies such as AstraZeneca, Daiichi Sankyo Company, Moderna Therapeutics, Enanta Pharmaceuticals, Codagenix, Inc., Meissa Vaccines, Inc., Calder Biosciences, Ark Biosciences, Vicebio, Immorna, CastleVax and others.
* Promising Respiratory Syncytial Virus Pipeline Therapies such as JNJ-53718678 2.5 mg/kg, Clesrovimab, RSV-A Memphis 37b, Matrix-M1 Adjuvant and others.
Stay ahead with the most recent pipeline outlook for Respiratory Syncytial Virus. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Respiratory Syncytial Virus Treatment Drugs [https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Respiratory Syncytial Virus Emerging Drugs Profile
* Clesrovimab: Merck Sharp & Dohme
Clesrovimab (MK-1654) is an investigational extended half-life monoclonal antibody (mAb) developed as a passive immunization for the prevention of RSV-associated medically attended lower respiratory infection (MALRI). Clesrovimab is being studied in infants (pre-term and full-term) to provide rapid, durable protection through their first RSV season with a single, fixed-dose administration. Currently, the drug is in the Phase III stage of its development for the treatment of Respiratory Syncytial Virus (RSV).
* IVX A12: AstraZeneca
IVX-A12 is a potential bivalent first-in-class combination vaccine candidate containing VLPs that incorporate stabilized prefusion F proteins from RSV and hMPV viruses. The FDA has granted IVX-A12 Fast Track designation in adults greater than or equal to 60 years of age. IVX-A12 is a liquid, refrigerator-stable formulation comprised of IVX-121, Icosavax's RSV prefusion F protein VLP vaccine candidate. Phase II data demonstrate that IVX-A12 elicits robust immune responses against both RSV and hMPV one month after vaccination and reconfirm previous immunogenicity data seen in the Phase I trial. The data are the first to demonstrate hMPV immune response in a Phase II combination vaccine trial. Currently, the drug is in the Phase II stage of its development for the treatment of Respiratory Syncytial Virus (RSV).
* MV-012-968: Meissa Vaccines, Inc
MV-012-968, an intranasal (needle-free), adjuvant-free, live attenuated vaccine candidate, to protect infants from RSV. MV-012-968 is well-tolerated, highly attenuated, and induces a strong systemic and mucosal IgA antibody response in RSV-naive children. Meissa is currently enrolling participants between the ages of six and 36 months in a Phase Ic clinical study at multiple sites in the U.S. to evaluate the safety and immunogenicity of MV-012-968. MV-012-968 was generated using the company's proprietary AttenuBlockTM synthetic biology platform with the goal of creating safe, potent, stable, and cost-effective intranasal vaccines. Currently, the drug is in the Phase I stage of its development for the treatment of Respiratory Syncytial Virus (RSV).
The Respiratory Syncytial Virus Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Respiratory Syncytial Virus with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Respiratory Syncytial Virus Treatment.
* Respiratory Syncytial Virus Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Respiratory Syncytial Virus Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Respiratory Syncytial Virus market
Explore groundbreaking therapies and clinical trials in the Respiratory Syncytial Virus Pipeline. Access DelveInsight's detailed report now! @ New Respiratory Syncytial Virus Drugs [https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Respiratory Syncytial Virus Companies
AstraZeneca, Daiichi Sankyo Company, Moderna Therapeutics, Enanta Pharmaceuticals, Codagenix, Inc., Meissa Vaccines, Inc., Calder Biosciences, Ark Biosciences, Vicebio, Immorna, CastleVax and others.
Respiratory Syncytial Virus (RSV) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical.
* Molecule Type
Respiratory Syncytial Virus Products have been categorized under various Molecule types such as
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
* Product Type
Unveil the future of Respiratory Syncytial Virus Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Respiratory Syncytial Virus Market Drivers and Barriers [https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Respiratory Syncytial Virus Pipeline Report
* Coverage- Global
* Respiratory Syncytial Virus Companies- AstraZeneca, Daiichi Sankyo Company, Moderna Therapeutics, Enanta Pharmaceuticals, Codagenix, Inc., Meissa Vaccines, Inc., Calder Biosciences, Ark Biosciences, Vicebio, Immorna, CastleVax and others.
* Respiratory Syncytial Virus Pipeline Therapies- JNJ-53718678 2.5 mg/kg, Clesrovimab, RSV-A Memphis 37b, Matrix-M1 Adjuvant and others.
* Respiratory Syncytial Virus Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Respiratory Syncytial Virus Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Respiratory Syncytial Virus Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Respiratory Syncytial Virus Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Respiratory Syncytial Virus (RSV): Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Respiratory Syncytial Virus (RSV) - DelveInsight's Analytical Perspective
* In-depth Commercial Assessment
* Respiratory Syncytial Virus (RSV) Collaboration Deals
* Late Stage Products (Phase III)
* Clesrovimab: Merck Sharp & Dohme
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* IVX A12: AstraZeneca
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* MV-012-968: Meissa Vaccines, Inc
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Respiratory Syncytial Virus (RSV) Key Companies
* Respiratory Syncytial Virus (RSV) Key Products
* Respiratory Syncytial Virus (RSV)- Unmet Needs
* Respiratory Syncytial Virus (RSV)- Market Drivers and Barriers
* Respiratory Syncytial Virus (RSV)- Future Perspectives and Conclusion
* Respiratory Syncytial Virus (RSV) Analyst Views
* Respiratory Syncytial Virus (RSV) Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=respiratory-syncytial-virus-clinical-trials-and-studies-2025-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Respiratory Syncytial Virus Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies here
News-ID: 3966138 • Views: …
More Releases from ABNewswire
The Trauma Therapist Institute Is Back With New Clinical Conversations For Septe …
Denver, CO - The Trauma Therapist Institute [https://www.traumatherapistinstitute.com/] is thrilled to be returning for another month with two brand new, free Clinical Conversations [https://www.traumatherapistinstitute.com/clinical-conversations] for trauma therapists who need a refresh, are seeking inspiration, or want to learn something new.
Each of these hour-long chats gives therapists the opportunity to speak about common topics that come up in the therapy room, offering raw, clinically useful conversations.
This month's conversations will explore how…
LinkedIn Is the New Stage - and Gen Z Is Stealing the Spotlight
UK/US-based brand consultant Nancy Ampaw unpacks why professional branding is Gen Z's smartest currency in 2025 and beyond
London, UK - August 25, 2025 - LinkedIn is no longer just a static job board. In 2025, it has become a strategic platform where Gen Z professionals actively shape their careers. As layoffs persist across industries and automated hiring systems filter out qualified applicants, younger workers are turning to LinkedIn to remain…
Canadian LumoCrafts Brings Hard-to-Find Scandinavian & Mid-Century Lighting to N …
New Canadian brand curates authentic European fixtures-sustainably made with natural materials-to counter mass-market lookalikes.
Image: https://www.abnewswire.com/upload/2025/08/4cc46eded74a9d46ce618ae5cee65d3c.jpg
Toronto, Ontario - In a market crowded with lookalike, mass-produced fixtures, LumoCrafts is bringing something different: a curated collection of authentic, minimalist Scandinavian and mid-century modern lighting-made in Europe and now available across Canada and the U.S. The Canadian brand, founded in 2023 and recently launched, is already gaining momentum with design-savvy Canadians. LumoCrafts champions natural…
Power by Google Veo 3! Edimakor Integrates Google's Veo 3 to Generate Sound-Read …
Edimakor, an all-in-one AI-powered video editor developed by HitPaw, today announced the integration of Google's Veo 3 technology. This marks a key step in AI-driven video creation, enabling the platform to generate realistic, sound-ready videos where visuals and audio are automatically synchronized. The update is expected to improve workflows for filmmakers, educators, businesses, and digital creators who want immersive video production without high costs or complex tools.
AI Image-to-Video Technology
Edimakor's AI…
More Releases for Respiratory
Prevalence Of Respiratory Diseases Fuels Demand For Respiratory Disposables: Key …
The Respiratory Disposables Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Respiratory Disposables Market Size During the Forecast Period?
The respiratory disposables market has seen rapid growth in recent years. It is expected to grow from $1.01 billion in 2024 to $1.15…
Transforming the Respiratory Monitoring Devices Market in 2025: Rising Incidence …
What Is the Expected Size and Growth Rate of the Respiratory Monitoring Devices Market?
The market size for respiratory monitoring devices has seen swift expansion in the recent past. The market's growth is projected to increase from $1.67 billion in 2024 to $1.87 billion in 2025, with a compound annual growth rate (CAGR) of 11.8%. A combination of factors such as the prevalence of respiratory ailments, an aging demographic, technological innovations,…
Transforming the Respiratory Monitoring Devices Market in 2025: Rising Incidence …
What Is the Expected Size and Growth Rate of the Respiratory Monitoring Devices Market?
The market size for respiratory monitoring devices has seen swift expansion in the recent past. The market's growth is projected to increase from $1.67 billion in 2024 to $1.87 billion in 2025, with a compound annual growth rate (CAGR) of 11.8%. A combination of factors such as the prevalence of respiratory ailments, an aging demographic, technological innovations,…
Molecular Respiratory Panels Market: Enhancing Accuracy and Speed in Respiratory …
Introduction
The global molecular respiratory panels market is rapidly evolving, driven by the need for faster, more accurate diagnostics in respiratory diseases. With respiratory infections and diseases becoming increasingly prevalent worldwide, accurate detection and timely diagnosis are critical to improving patient outcomes. Molecular respiratory panels, which utilize advanced molecular techniques like PCR (Polymerase Chain Reaction) and other nucleic acid-based methods, enable the rapid identification of pathogens responsible for respiratory conditions. These…
Tackling Respiratory Challenges: Lower Respiratory Tract Therapeutics Market 202 …
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Lower Respiratory Tract Therapeutics Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $48.37 billion In…
Respiratory Assist Devices Market - Breathing Uninterrupted: Innovating Respirat …
Newark, New Castle, USA - new report, titled Respiratory Assist Devices Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Respiratory Assist Devices market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Respiratory Assist Devices market. The report offers an overview of…
